A new antibody has been developed to target Neuropilin-2 (NRP2), a receptor involved in processes like lymphangiogenesis, cancer, and inflammation. This antibody, unlike existing ones, is specifically designed for companion diagnostics. Tests using various methods confirm its ability to detect different NRP2 isoforms without reacting with NRP1. The antibody reveals high NRP2 levels in granulomas from sarcoidosis patient skin and lung biopsies. This novel anti-NRP2 antibody could become a valuable tool for diagnosing sarcoidosis and other conditions linked to NRP2.
View the full article in the journal and see how IKOSA supported the research